Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 11%

Bulls say

Arvinas is a clinical-stage biotechnology company with a promising pipeline of protein degradation therapies targeting a wide range of diseases. The company's focus on targeting disease-causing proteins through its PROTAC platform shows great potential for improving patients' lives. Despite the risks associated with clinical trials and competition in the market, Arvinas' strong financial position and partnerships with companies like Novartis demonstrate its potential to achieve success in the future and generate significant returns for investors.

Bears say

Arvinas is currently progressing its protein degradation therapies for various oncology and neurology-related diseases, including vepdegestrant for breast cancer, ARV-393 for non-Hodgkin Lymphoma, and ARV-102 for neurodegenerative disorders. However, the market may not fully credit the company until clinical benefits are demonstrated, despite ARV-102's compelling biomarker data, as its main competitor, Biogen, has not shown significant reductions in LRRK2 levels with their inhibitor. Arvinas' management remains confident in their product's potential, but a positive phase 2b result from Biogen could validate the LRRK2 pathway in the eyes of the market.

Arvinas Inc (ARVN) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 9 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.